NCT02439970View on ClinicalTrials.gov

A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease

PHASE3TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

January 30, 2016

Study Completion Date

January 30, 2016

Conditions
Cytomegalovirus Disease
Interventions
DRUG

Brincidofovir

DRUG

Valganciclovir

Trial Locations (3)

80045

University of Colorado Hospital/Health Science Center, Aurora

90057

St. Vincent Medical Center, Los Angeles

06520

Yale New Haven Hospital, New Haven

Sponsors
All Listed Sponsors
lead

Jazz Pharmaceuticals

INDUSTRY